



ISSN: 1681-150x SAOJ

## CPD QUESTIONNAIRE. AUGUST 2023 VOL 22 NO 3

	D-printed cable tie-assisted static progressive splints for			d.	Osteochondral autogra
	ted flexion contractures of the proximal phalangeal joint: proof of concept study (Rocher A, O'Connor M, Marais LC)		_	e.	Manipulation under an
1.	PLA (polylactic acid) 3D-printable material:			7.	What percentage of t
a.	Is relatively expensive compared to other printable plastics	Α			provided by the priva
b.	Is toxic to humans	В			16%
C.	Can only be printed on expensive commercial 3D printers	С			30%
d.	Is biodegradable	D			39%
e.	Has a tensile strength of 370 megapascals	Е			51%
2.	Regarding the use of a cable tie to effect stretch:				64%
a.	A cable tie allows dynamic tension	Α		8.	Which domain had th in the Hospital Consu
b.	The cable tie will stretch over time	В			and Systems (HCAHF
C.	The cable tie should be applied parallel to the lever arm of the contracture	С			Nurse communication
d.	Cable ties are used in commercially available splints	D			Doctor communication
e.	The cable tie allows re-application at the same amount	Е			Communication about
_	of tension	_			Cleanliness of hospital
3.	Which of the following proposed benefits of utilising 3D printed splints in practice is <i>incorrect</i> ?				Discharge information te use of a mobile soft
a.	3D-printed splints are good for prototyping different design ideas	Α		en	anagement of open tik vironment (Mzamo S,
٥.	Learning to design splints on 3D software is easy	В			arais LC)
٥.	Design files can be easily shared for use at other centres	С		9.	What was the statisti from referral to asses
d.	Designs can be easily scaled for different finger dimensions	D			the two groups?
€.	3D-design software is open source	Е		a.	5 hours VULA group a
1.	3D splints for the hand have been used previously for which application, as discussed in this article?			b.	10 hours VULA group
а.	Burn contractures	Α		C.	5 hours VULA group a
٥.	Dupuytren's disease	В		d.	20 hours VULA group
	Finger amputations	С		e.	6 hours VULA group a
	Mallet fingers	D		10.	Comparing referral m
	Jersey fingers	Ε			our study showed a s between using the VI
	et's talk business: a public-private partnership in soft tissue	,			rate. This may be due
kn	nee surgery (Yu WC, Le Roux J, Von Bormann R, Held M)			a.	Improved initial manag
5.	What is the primary goal of public-private partnerships (PPPs) in South African orthopaedic surgery departments	?		b.	Reduced timing of refe
а.	Increase patient volumes in private hospitals	Α		C.	Reduced timing of refe
	Reduce waiting time for surgery in public hospitals	В		d.	Early antibiotics admin
C.	Generate revenue for non-profit organisations	С		e.	None of the above
d.	Improve efficiency and infrastructure in public hospitals	D		11.	What was the primary
Э.	Enhance the training capacity of private hospitals	Ε		a.	Initial management and
	What was the most common procedure performed during the study period?			b.	groups Efficiency of orthopaed
٦.	Anterior cruciate ligament reconstruction	Α		C.	Quality of orthopaedic
o. O.	Medial patellofemoral ligament reconstruction	В			Initial management of
С.		С			Referral delays between
٠.	mornoode debridement ± repair		_	٥.	. tororran dolayo botwee

d.	Osteochondral autograft transfer (OAT)	D
e.	Manipulation under anaesthesia	Ε
7.	What percentage of the total surgical training time was provided by the private hospital?	
a.	16%	Α
b.	30%	В
C.	39%	С
d.	51%	D
e.	64%	Ε
8.	Which domain had the lowest patient satisfaction score in the Hospital Consumer Assessment of Health Providers and Systems (HCAHPS) survey?	;
a.	Nurse communication	Α
b.	Doctor communication	В
C.	Communication about medicines	С
d.	Cleanliness of hospital environment	D
e.	Discharge information	Е
m er Ma	ne use of a mobile software application to improve the anagement of open tibia fractures in a resource-constraine avironment (Mzamo S, Rajpaul J, O'Connor M, Arnold J, arais LC)	d
9.	What was the statistically significant difference in time from referral to assessment at the tertiary centre between the two groups?	
a.	5 hours VULA group and 6 hours HWRL group	Α
b.	10 hours VULA group and 6 hours HWRL group	В
C.	5 hours VULA group and 20 hours HWRL group	С
d.	20 hours VULA group and 4 hours HWRL group	D
e.	6 hours VULA group and 6 hours HWRL group	Ε
10.	Comparing referral methods and complication rates, our study showed a statistically significant association between using the VULA app and a reduced complication rate. This may be due to:	
a.	Improved initial management	Α
b.	Reduced timing of referral from injury	В
C.	Reduced timing of referral from the base hospital	С
d.	Early antibiotics administration	D
e.	None of the above	Е
11.	What was the primary outcome of interest of this study?	
a.	Initial management and referral delays between the two groups	Α
b.	Efficiency of orthopaedic patient transfer	В
C.	Quality of orthopaedic referrals	С
d.		
u.	Initial management of open tibial fractures	D

Page 120 SA Orthop J 2023;22(3)

(F	am-negative cover antibiotic prophylaxis in open fractures erreira N, Tsang S-TJ, Jansen van Rensburg A, Venter R, stein GZ)	?
12.	The most common causative pathogen of post-traumatic infections is:	
a.	Proteus mirabilis	Α
b.	Streptococcus pyogenes	В
C.	Pseudomonas aeruginosa	С
d.	Staphylococcus aureus	D
e.	Escherichia coli	Ε
13.	Gram-negative associated fracture-related infections (FRI) appear to be increasing. The prevalence of Gram-negative associated FRI in the current presented series was:	
a.	15%	Α
b.	25%	В
C.	35%	С
d.	45%	D
e.	55%	Е
14.	It is widely accepted that Gram-negative antibiotic cover should be added in which of the following clinical scenarios?	
a.	Fracture surgery lasting more than three hours	Α
b.	Higher-grade open fractures (Gustilo-Anderson 3)	В
C.	As preoperative prophylaxis in all fracture surgery cases	С
d.	As postoperative prophylaxis in all open fracture surgery cases	D
e.	As prophylaxis in shoulder arthroplasty cases	Е
15.	Which percentage of open fracture cases only received coverage against Gram-positive pathogens, according to a multicentre audit of major United Kingdom trauma centres?	•
a.	83%	Α
b.	78%	В
C.	73%	С
d.	67%	D
e.	33%	Ε
VO	ne role of bioceramics in the management of osteomyelitic ids (Ferreira N, Epstein GZ)	
16.	What advantage does the use of bioceramics have over cement spacers in the management of dead space when treating chronic osteomyelitis?	
a.	They have far better long-term outcomes	Α
b.	They do not need to be removed	В
C.	They elute much higher concentrations of antibiotics	С
d.	They are cheaper	D
e.	They have broader antimicrobial activity	Ε

Unexpected high prevalence of Gram-negative pathogens in fracture-related infection: is it time to consider extended

17.	Which dead space management strategy is <i>not</i> currently available in South Africa?	
a.	The Lautenbach technique	Α
b.	Cement spacers and cement nails	В
C.	Osteoset-T	С
d.	Cerament-V	D
e.	Cerament-G	Е
18.	Which statement regarding bioactive glass is <i>not</i> true?	
a.	They are effective against Gram-positive and Gram-negative organisms.	Α
b.	Cation exchange leads to a high local pH	В
C.	They are highly versatile and can be moulded to assist in the management of voids following segmental resections of necrotic bone	С
d.	They stimulate angiogenesis by an increase in vascular endothelial growth factor	D
e.	They are osteoconductive and osteoinductive	Е
	,	
Α	case of tenofovir-induced extreme osteopaenia (Theron M, arrison WD, Ferreira N)	
A Ha	case of tenofovir-induced extreme osteopaenia (Theron M,	
A Ha	case of tenofovir-induced extreme osteopaenia (Theron M, arrison WD, Ferreira N)	A
A Ha	case of tenofovir-induced extreme osteopaenia (Theron M, arrison WD, Ferreira N) Tenofovir is form of:	
19.	case of tenofovir-induced extreme osteopaenia (Theron M, arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor	A
19. a. b.	case of tenofovir-induced extreme osteopaenia (Theron M, arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor  Non-nucleoside reverse transcriptase inhibitor	A B
19. a. b. c. d. e.	case of tenofovir-induced extreme osteopaenia (Theron M, Arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor  Non-nucleoside reverse transcriptase inhibitor  Protease inhibitor  Fusion inhibitor  Integrase strand transfer inhibitor	A B C D
19. a. b. c. d. e.	case of tenofovir-induced extreme osteopaenia (Theron M, Arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor  Non-nucleoside reverse transcriptase inhibitor  Protease inhibitor  Fusion inhibitor	A B C D
19. a. b. c. d. e.	case of tenofovir-induced extreme osteopaenia (Theron M, Arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor  Non-nucleoside reverse transcriptase inhibitor  Protease inhibitor  Fusion inhibitor  Integrase strand transfer inhibitor  Osteopaenia is a common complication of tenofovir use, w	A B C D
A Ha	case of tenofovir-induced extreme osteopaenia (Theron M, Arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor  Non-nucleoside reverse transcriptase inhibitor  Protease inhibitor  Fusion inhibitor  Integrase strand transfer inhibitor  Osteopaenia is a common complication of tenofovir use, was a frequency of around:  30%	A B C D E
19. a. b. c. d. e. 20.	case of tenofovir-induced extreme osteopaenia (Theron M, Arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor  Non-nucleoside reverse transcriptase inhibitor  Protease inhibitor  Fusion inhibitor  Integrase strand transfer inhibitor  Osteopaenia is a common complication of tenofovir use, was frequency of around:  30%	A B C D E
19. a. b. c. d. e. 20. a. b.	case of tenofovir-induced extreme osteopaenia (Theron M, Arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor  Non-nucleoside reverse transcriptase inhibitor  Protease inhibitor  Fusion inhibitor  Integrase strand transfer inhibitor  Osteopaenia is a common complication of tenofovir use, was frequency of around:  30%  40%  50%	A B C D E ith A B
A Ha 19. a. b. c. d. e. 20. a. b.	case of tenofovir-induced extreme osteopaenia (Theron M, Arrison WD, Ferreira N)  Tenofovir is form of:  Nucleoside reverse transcriptase inhibitor  Non-nucleoside reverse transcriptase inhibitor  Protease inhibitor  Fusion inhibitor  Integrase strand transfer inhibitor  Osteopaenia is a common complication of tenofovir use, wa a frequency of around:  30%  40%  50%	A B C D E ith A B C

## Subscribers and other recipients of SAOJ visit our new CPD portal at www.mpconsulting.co.za

- Register with your email address as username and MP number with seven digits as your password and then click on the icon "Journal CPD".
- Scroll down until you get the correct journal. On the right hand side is an
  option "ACCESS". This will allow you to answer the questions. If you still can
  not access please send your Name and MP number to cpd@medpharm. co.za in order to gain access to the questions.
- Once you click on this icon, there is an option below the title of the journal: Click to read this issue online.
  Complete the questionnaire and click on submit.
  Your points are automatically submitted to the relevant authority.

- Please call MPC Helpdesk if you have any questions: 0861 111 335.

Medical Practice Consulting: Client Support Center: +27121117001 Office – Switchboard: +27121117000



MDB015/069/01/2023

SA Orthop J 2023;22(3) Page 122